JP2020504112A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504112A5 JP2020504112A5 JP2019533594A JP2019533594A JP2020504112A5 JP 2020504112 A5 JP2020504112 A5 JP 2020504112A5 JP 2019533594 A JP2019533594 A JP 2019533594A JP 2019533594 A JP2019533594 A JP 2019533594A JP 2020504112 A5 JP2020504112 A5 JP 2020504112A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fab
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022167563A JP7622017B2 (ja) | 2016-12-21 | 2022-10-19 | 造血幹細胞を除去するための抗体薬物結合体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437622P | 2016-12-21 | 2016-12-21 | |
| US62/437,622 | 2016-12-21 | ||
| US201762520854P | 2017-06-16 | 2017-06-16 | |
| US62/520,854 | 2017-06-16 | ||
| PCT/IB2017/058159 WO2018116178A1 (en) | 2016-12-21 | 2017-12-19 | Antibody drug conjugates for ablating hematopoietic stem cells |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167563A Division JP7622017B2 (ja) | 2016-12-21 | 2022-10-19 | 造血幹細胞を除去するための抗体薬物結合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504112A JP2020504112A (ja) | 2020-02-06 |
| JP2020504112A5 true JP2020504112A5 (https=) | 2021-02-04 |
| JP7181203B2 JP7181203B2 (ja) | 2022-11-30 |
Family
ID=60957364
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533594A Active JP7181203B2 (ja) | 2016-12-21 | 2017-12-19 | 造血幹細胞を除去するための抗体薬物結合体 |
| JP2022167563A Active JP7622017B2 (ja) | 2016-12-21 | 2022-10-19 | 造血幹細胞を除去するための抗体薬物結合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022167563A Active JP7622017B2 (ja) | 2016-12-21 | 2022-10-19 | 造血幹細胞を除去するための抗体薬物結合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11357864B2 (https=) |
| EP (1) | EP3558389A1 (https=) |
| JP (2) | JP7181203B2 (https=) |
| KR (2) | KR20240093751A (https=) |
| CN (2) | CN110099697B (https=) |
| AU (1) | AU2017383458C1 (https=) |
| BR (1) | BR112019012483A2 (https=) |
| CA (1) | CA3045592A1 (https=) |
| CL (1) | CL2019001745A1 (https=) |
| CO (1) | CO2019006455A2 (https=) |
| CR (1) | CR20190296A (https=) |
| CU (1) | CU24644B1 (https=) |
| EA (1) | EA201991526A1 (https=) |
| EC (1) | ECSP19044625A (https=) |
| IL (2) | IL300567A (https=) |
| JO (1) | JOP20190155B1 (https=) |
| MA (1) | MA47231A (https=) |
| MX (1) | MX2019007582A (https=) |
| MY (1) | MY193985A (https=) |
| PE (1) | PE20191539A1 (https=) |
| PH (1) | PH12019501330A1 (https=) |
| SA (1) | SA519402188B1 (https=) |
| TW (2) | TWI778994B (https=) |
| WO (1) | WO2018116178A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2953976B1 (en) * | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| WO2017191579A1 (en) | 2016-05-05 | 2017-11-09 | Novartis Ag | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| IL263744B2 (en) * | 2016-06-17 | 2023-11-01 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117 plus cells |
| JP2021526525A (ja) * | 2018-06-07 | 2021-10-07 | マジェンタ セラピューティクス インコーポレイテッドＭａｇｅｎｔａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 抗体薬物コンジュゲート（ａｄｃｓ）を用いた治療方法 |
| UY38265A (es) * | 2018-06-20 | 2020-01-31 | Novartis Ag | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas |
| CN112739339B (zh) * | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| CA3107383A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy |
| AU2019366960A1 (en) * | 2018-10-23 | 2021-05-27 | Regeneron Pharmaceuticals, Inc. | Fc silenced antibody drug conjugates (ADCs) and uses thereof |
| US20230053449A1 (en) * | 2018-10-31 | 2023-02-23 | Novartis Ag | Dc-sign antibody drug conjugates |
| EA202190986A1 (ru) * | 2018-11-26 | 2021-12-14 | Фоти Севен, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit |
| EP3894387A4 (en) | 2018-12-12 | 2023-07-19 | Levim Biotech LLP | ACYLATION PROCESSES FOR THE PRODUCTION OF N-SUBSTITUTED PEPTIDES |
| JP2022535527A (ja) * | 2019-06-04 | 2022-08-09 | マジェンタ セラピューティクス インコーポレイテッド | 自己免疫疾患を治療するための方法および組成物 |
| WO2021022678A1 (zh) * | 2019-08-07 | 2021-02-11 | 烟台迈百瑞国际生物医药股份有限公司 | 一种抗体药物偶联物及其应用 |
| CN116183899B (zh) * | 2023-04-28 | 2023-06-30 | 天津市协和医药科技集团有限公司 | 一种吖啶酯标记抗体保存液的制备方法 |
| WO2025051254A1 (zh) * | 2023-09-08 | 2025-03-13 | 信达生物制药(苏州)有限公司 | 半胱氨酸改造的抗体和免疫缀合物 |
| WO2025080282A1 (en) * | 2023-10-12 | 2025-04-17 | Memorial Sloan-Kettering Cancer Center | Combination therapy with clk/dyrk inhibitors and bcl2 inhibitors to treat leukemia |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| CA2109528A1 (en) | 1991-05-01 | 1992-11-02 | Gregory A. Prince | A method for treating infectious respiratory diseases |
| US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
| US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
| ATE508733T1 (de) | 1996-03-04 | 2011-05-15 | Penn State Res Found | Materialien und verfahren zur steigerung der zellulären internalisierung |
| US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| CA2277801C (en) | 1997-01-16 | 2002-10-15 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| WO1999066903A2 (en) | 1998-06-24 | 1999-12-29 | Advanced Inhalation Research, Inc. | Large porous particles emitted from an inhaler |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| WO2003068821A2 (en) | 2002-02-14 | 2003-08-21 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| AU2003245752A1 (en) | 2002-06-28 | 2004-01-19 | Bio Transplant, Inc. | Process for promoting graft acceptance by depletion of hematopoietic stem cells |
| JP2007525438A (ja) | 2003-03-24 | 2007-09-06 | ザイモジェネティクス， インコーポレイテッド | 抗ｉｌ−２２ｒａ抗体および結合パートナー、ならびに炎症における使用法 |
| TWI395754B (zh) | 2006-04-24 | 2013-05-11 | Amgen Inc | 人類化之ｃ-ｋｉｔ抗體 |
| WO2008067115A2 (en) | 2006-11-03 | 2008-06-05 | The Board Of Trustees Of The Leland Stanford Junior University | Selective immunodepletion of endogenous stem cell niche for engraftment |
| US8540517B2 (en) | 2006-11-27 | 2013-09-24 | Pharos Innovations, Llc | Calculating a behavioral path based on a statistical profile |
| EP2711018A1 (en) | 2009-06-22 | 2014-03-26 | MedImmune, LLC | Engineered Fc regions for site-specific conjugation |
| US9540443B2 (en) * | 2011-01-26 | 2017-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies |
| AR086044A1 (es) | 2011-05-12 | 2013-11-13 | Imclone Llc | Anticuerpos que se unen especificamente a un dominio extracelular de c-kit y usos de los mismos |
| NZ630363A (en) | 2012-07-25 | 2018-09-28 | Celldex Therapeutics Inc | Anti-kit antibodies and uses thereof |
| EP2953976B1 (en) | 2013-02-08 | 2021-03-24 | Novartis Ag | Specific sites for modifying antibodies to make immunoconjugates |
| ES2701051T3 (es) * | 2013-03-15 | 2019-02-20 | Novartis Ag | Conjugados de anticuerpo-fármaco |
| JP2017509337A (ja) * | 2014-03-12 | 2017-04-06 | ノバルティス アーゲー | イムノコンジュゲートを作製する抗体を修飾するための特定部位 |
| CA2951368A1 (en) | 2014-06-13 | 2015-12-17 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| WO2016020791A1 (en) | 2014-08-05 | 2016-02-11 | Novartis Ag | Ckit antibody drug conjugates |
| EP3215519A1 (en) | 2014-11-06 | 2017-09-13 | Novartis AG | Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase |
| HK1256681A1 (zh) * | 2015-04-06 | 2019-10-04 | President And Fellows Of Harvard College | 用於非清髓性预处理的组合物和方法 |
| US20190194315A1 (en) * | 2015-06-17 | 2019-06-27 | Novartis Ag | Antibody drug conjugates |
| IL263744B2 (en) * | 2016-06-17 | 2023-11-01 | Magenta Therapeutics Inc | Compositions and methods for the depletion of cd117 plus cells |
-
2017
- 2017-12-19 KR KR1020247016376A patent/KR20240093751A/ko not_active Ceased
- 2017-12-19 PE PE2019001291A patent/PE20191539A1/es unknown
- 2017-12-19 CU CU2019000061A patent/CU24644B1/es unknown
- 2017-12-19 JP JP2019533594A patent/JP7181203B2/ja active Active
- 2017-12-19 CR CR20190296A patent/CR20190296A/es unknown
- 2017-12-19 JO JOJO/P/2019/0155A patent/JOP20190155B1/ar active
- 2017-12-19 CN CN201780079504.9A patent/CN110099697B/zh active Active
- 2017-12-19 US US16/470,897 patent/US11357864B2/en active Active
- 2017-12-19 EA EA201991526A patent/EA201991526A1/ru unknown
- 2017-12-19 IL IL300567A patent/IL300567A/en unknown
- 2017-12-19 MA MA047231A patent/MA47231A/fr unknown
- 2017-12-19 TW TW106144615A patent/TWI778994B/zh active
- 2017-12-19 CA CA3045592A patent/CA3045592A1/en active Pending
- 2017-12-19 MY MYPI2019003457A patent/MY193985A/en unknown
- 2017-12-19 CN CN202311642832.9A patent/CN117653740A/zh active Pending
- 2017-12-19 WO PCT/IB2017/058159 patent/WO2018116178A1/en not_active Ceased
- 2017-12-19 BR BR112019012483A patent/BR112019012483A2/pt unknown
- 2017-12-19 TW TW111133640A patent/TWI852077B/zh active
- 2017-12-19 KR KR1020197020530A patent/KR20190099238A/ko not_active Ceased
- 2017-12-19 EP EP17829033.4A patent/EP3558389A1/en active Pending
- 2017-12-19 AU AU2017383458A patent/AU2017383458C1/en active Active
- 2017-12-19 MX MX2019007582A patent/MX2019007582A/es unknown
-
2019
- 2019-06-13 PH PH12019501330A patent/PH12019501330A1/en unknown
- 2019-06-18 IL IL267478A patent/IL267478B2/en unknown
- 2019-06-19 CO CONC2019/0006455A patent/CO2019006455A2/es unknown
- 2019-06-20 CL CL2019001745A patent/CL2019001745A1/es unknown
- 2019-06-20 SA SA519402188A patent/SA519402188B1/ar unknown
- 2019-06-21 EC ECSENADI201944625A patent/ECSP19044625A/es unknown
-
2022
- 2022-06-06 US US17/833,077 patent/US12171839B2/en active Active
- 2022-10-19 JP JP2022167563A patent/JP7622017B2/ja active Active
-
2024
- 2024-11-05 US US18/937,914 patent/US20250064964A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020504112A5 (https=) | ||
| JP7622017B2 (ja) | 造血幹細胞を除去するための抗体薬物結合体 | |
| US20240424012A1 (en) | Combinations and uses thereof | |
| JP7526099B2 (ja) | 抗ｃｄ３８抗体の皮下投薬 | |
| JP6621447B2 (ja) | 抗ｃｄ３８抗体 | |
| RU2684468C2 (ru) | Новые конъюгаты антител и их применения | |
| TWI511978B (zh) | 結合ｉｌ－１７ａ及ｉｌ－１７ｆ之抗體分子 | |
| EP3678700B1 (en) | Compounds for reducing the viscosity of biological formulations | |
| RU2009149462A (ru) | АНТИТЕЛА ПРОТИВ NRR Notch1 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2014116878A (ru) | Цитотоксические пептиды и их конъюгаты антитело-лекарственное средство | |
| JP2022537289A5 (https=) | ||
| JP2023542412A (ja) | ピロロベンゾジアゼピン抗体複合体及びその使用 | |
| AU2012296905A1 (en) | Combination therapy with an anti - CD19 antibody and a purine analog | |
| CN119546345A (zh) | 使用抗cd22抗体寡核苷酸缀合物治疗癌症的方法 | |
| JP2025130076A (ja) | 抗ｃｄ３８抗体及びその使用 | |
| RU2021100973A (ru) | Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток | |
| TWI853393B (zh) | 人源化抗人類神經降壓素受體1抗體及其應用 | |
| EP4410836A1 (en) | Anti-cd47 antibody for combined treatment of blood tumor | |
| RU2810953C2 (ru) | Подкожное дозирование антител к cd38 | |
| WO2025262130A1 (en) | Antibody drug conjugate | |
| JP2025529623A (ja) | ヒト化抗ヒトニューロテンシン受容体１抗体及びそれらの使用 | |
| WO2024118106A1 (en) | Cancer treatment with an ror1 antibody immunoconjugate and a btk inhibitor | |
| TW202321308A (zh) | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 | |
| RU2022126092A (ru) | Конъюгаты антитела и лекарственного средства для разрушения гемопоэтических стволовых клеток |